SAN DIEGO--(BUSINESS WIRE)--Apr. 9, 2018--
Tandem Diabetes Care®, Inc. (NASDAQ: tndm), a medical device company and
manufacturer of the only touchscreen insulin pumps available in the
United States, today announced that it has entered into a distribution
agreement with Movi SpA to commercialize Tandem’s t:slim X2™ Insulin
Pump in Italy.
“Partnering with experienced insulin pump distributors is key to our
international commercialization strategy as we work to expand available
insulin pump options for patients and healthcare providers worldwide,”
said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. “Movi
shares in our passion to help improve the lives of people with diabetes,
and we look forward to working with them to bring the t:slim X2 Insulin
Pump to the diabetes communities in Italy.”
“We are proud to offer the t:slim X2 Insulin Pump to people with type 1
diabetes and healthcare providers in Italy, to provide an innovative and
reliable alternative to the current market option,” said Enrico Piero
Bassani, President of Movi. “We thank Tandem Diabetes Care for trusting
us as their distributor for Italy, and we look forward to bringing the
benefits of Tandem’s products to the patients and clinics that we
service.”
Under the terms of the arrangement Movi will perform all sales,
marketing and customer training and support for Tandem’s products.
Timing for availability of Tandem products in Italy has not yet been
announced.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company dedicated to improving the lives of people
with diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach to
the design, development and commercialization of products for people
with diabetes who use insulin. Tandem manufactures and sells the t:slim
X2™ Insulin Pump, the only pump capable of remote feature updates using
a personal computer and the only available pump with Dexcom G5® Mobile
CGM integration. Tandem is based in San Diego, California.
Tandem Diabetes Care and t:slim X2 are either registered trademarks or
trademarks of Tandem Diabetes Care, Inc. in the United States and/or
other countries. Dexcom and Dexcom G5 are registered trademarks of
Dexcom, Inc. All other trademarks are the property of their respective
owners.
Forward Looking Statement
This press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected
in the forward-looking statements. These forward-looking statements
relate to, among other things, the Company’s distribution agreement with
Movi SpA and the anticipated availability of the Company’s products
outside the United States. The Company’s actual results may differ
materially from those indicated in these forward-looking statements due
to numerous risks and uncertainties, including: risks associated with
the development of new products generally, including possible delays in
the Company’s product development programs; possible future actions of
regulatory bodies or governmental authorities, including the potential
that the Company may not achieve CE Mark approval for the Company’s
products when anticipated; the potential that the Company’s agreement
with Movi SpA could be terminated; as well as other risks identified in
Tandem’s most recent Annual Report on Form 10-K, and other documents
that we file with the Securities and Exchange Commission. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release. The
companies undertake no obligation to update or review any
forward-looking statement in this press release because of new
information, future events or other factors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180409005352/en/
Source: Tandem Diabetes Care, Inc.
Tandem Diabetes Care:
Media:
Steve Sabicer, 714-907-6264
ssabicer@thesabicergroup.com
or
Investors:
Susan
Morrison, 858-366-6900 x7005
IR@tandemdiabetes.com
or
Movi
SpA:
tandemdiabetes@movigroup.com
